Sweden A relative newcomer to the Nordic countries, Otsuka has successfully built a strong foothold in the region. Pontus Billstam, managing director for the Nordics & Benelux, looks back at the main milestones in the affiliate’s development and explains the importance of the Nordic region for Otsuka as a testbed for…
Spain Rafael Mella, general manager of Nordic Pharma Spain & Portugal, highlights the steps he has taken to set-up the foundations for the company in the Spanish market and how he has overcome the challenges of the fragmented healthcare system. Furthermore, he gives insight into the Nordic’s game-changing Rheumatoid Arthritis product,…
France Vincent Leonhardt explains how the French administration’s zeal for life science innovation can actually place pressure on some pharma SMEs. He also discusses the challenges he faced during his first 2.5 years at the helm of Nordic Pharma in France. Over the last decade, Nordic Pharma has gained renown…
Switzerland Heike Behn, reveals how her number one priority at Nordic Pharma Switzerland, the group’s’newest affiliate, is to develop their rheumatology business, building on their gynecology platform; how the speed with which they can approach the customer is a major competitive advantage for the company; and how Switzerland´s approval process, when…
Medicines Country Manager of Norpharma, Denmark, discusses how the company has been able to remain a market competitor while maintaining satisfactory payer prices. Since Norpharma’s founding in 1192, what are some of its key areas and products? We work in a number of strategic areas; pain management is where our heritage…
Sweden Anders Blanck of Lif Sweden discusses the Swedish healthcare system, why it’s contributing to the plunging profit margins in the pharma market, and the Swedish government’s heavy emphasis on cost-effectiveness. Technically we have 21 different healthcare systems in our country, and they all have their own political bodies, run…
Dialysis The general manager of Baxter in the Nordic region discusses the concept of home care, and how brand new technologies currently being tested in Sweden should mean that soon, dialysis treatment will shift from the hospital to the home around the world. Could you please give us a brief introduction…
Generics Janssen has historically had a very strong focus on emerging markets. In today’s world, where growth for the pharmaceutical industry overwhelmingly comes from emerging markets, where do we find the Nordics? What is the relevance of the Nordics for the country’s global footprint? Jansen has preserved the cluster model. We…
Bavarian Nordic If there is one thing that successful Danish companies have in common with one another, it is the clear recognition of abundant opportunities outside the motherland. “Danish companies’ strengths lie in their ability to build on what they have inherited from Denmark but to also look outward and be…
Denmark “The Nordic region—the ‘quiet North’ as it could have been called—counterbalances the turbulence in Southern Europe,” says Zinta Krumins, managing director Nordics, Boehringer Ingelheim, when asked about the relevance of the Nordics to the company. “The Nordics is a very stable region, with small but reasonable growth prospects, very good…
Nordic Drugs Could you begin by giving a short introduction to Nordic Drugs and its current position within the structure of owner Nordic Group? Nordic Drugs started as a 100% owned subsidiary of Ferring in January 1995. Several years later, in 1998, we were divested out from Ferring. Today we are owned…
Gilead Nordics As the blockbuster sales model fades, the rush is on for a new formula for growth, termed ‘Good growth’ by Pharmaceutical Executive: niched, balanced & sustainable with high margins from protected pricing, more patient-friendly than patent-centric and with revenues coming from a deep reservoir of unmet medical need. How well…
See our Cookie Privacy Policy Here